Debanjana Chatterjee
Stock Analyst at Jones Trading
(0.04)
# 4,118
Out of 4,814 analysts
7
Total ratings
16.67%
Success rate
-32.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KALV KalVista Pharmaceuticals | Maintains: Buy | $30 | $12.09 | +148.14% | 2 | Mar 26, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Buy | $23 | $4.57 | +403.28% | 1 | Mar 13, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $42 | $2.21 | +1,800.45% | 1 | Jan 27, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Hold | n/a | $12.65 | - | 1 | Dec 11, 2024 | |
| PHVS Pharvaris | Initiates: Buy | $46 | $14.00 | +228.57% | 1 | Sep 19, 2024 | |
| NTLA Intellia Therapeutics | Initiates: Buy | $41 | $7.27 | +464.35% | 1 | Sep 17, 2024 |
KalVista Pharmaceuticals
Mar 26, 2025
Maintains: Buy
Price Target: $30
Current: $12.09
Upside: +148.14%
Contineum Therapeutics
Mar 13, 2025
Initiates: Buy
Price Target: $23
Current: $4.57
Upside: +403.28%
Sagimet Biosciences
Jan 27, 2025
Initiates: Buy
Price Target: $42
Current: $2.21
Upside: +1,800.45%
Spyre Therapeutics
Dec 11, 2024
Initiates: Hold
Price Target: n/a
Current: $12.65
Upside: -
Pharvaris
Sep 19, 2024
Initiates: Buy
Price Target: $46
Current: $14.00
Upside: +228.57%
Intellia Therapeutics
Sep 17, 2024
Initiates: Buy
Price Target: $41
Current: $7.27
Upside: +464.35%